Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$78.26 USD

78.26
2,282,701

+0.24 (0.31%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $78.32 +0.06 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs

Allergan (AGN) gets CRL for uterine fibroids candidate, Esmya. Merck (MRK) and Bristol-Myers' (BMY) PD-L1 inhibitors get FDA approval for expanded labels.

    Novartis Breast Cancer Drug Meets Primary Goal in Phase III

    Novartis' (NVS) late-stage candidate, BYL719, meets primary endpoint in SOLAR trial on advanced breast cancer patients.

      Ironwood's Linzess Gets Approval in Japan for New Indication

      Ironwood Pharmaceuticals (IRWD) along with its partner Astellas Pharma announces approval of Linzess in Japan for a new indication - chronic constipation.

        Japan Nods to AstraZeneca's Tagrisso for First-Line NSCLC

        AstraZeneca (AZN) receives approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the label expansion of Tagrisso.

          Merck, Eisai Get FDA Approval for Lenvima Label Expansion

          Merck (MRK) and Japanese partner Eisai gains an FDA approval for Lenvima label expansion. The anti-cancer drug receives the regulatory body's nod for the first line treatment of unresectable HCC.

            Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication

            Bayer's (BAYRY) Monsanto subsidiary faces $289 million fine in Roundup lawsuit. Merck/Eisai's drug Lenvima gets FDA approval to treat the most common form of liver cancer.

              Mark Vickery headshot

              Top Research Reports for Cisco, AstraZeneca & Enbridge

              Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems (CSCO), AstraZeneca (AZN) and Enbridge (ENB).

                Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs

                Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company announces restructuring initiative to improve operational efficiency.

                  Here's Why Merck (MRK) Stock is Up Since Q2 Earnings Release

                  Merck's (MRK) stock is up 4.2% since announcement of earnings in July. Let us have a look at the reasons for the same.

                    The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

                    The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

                      Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus

                      Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.

                        What's in the Cards for Perrigo (PRGO) This Earnings Season?

                        Perrigo's (PRGO) product purchases and introductions in the Rx segment are expected to boost sales.

                          Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down

                          Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the second quarter. The company will be separated into two entities for better management.

                            Pharma Stock Roundup: PFE Dominates Headlines, BMY Drug Gets EU Approval

                            Pfizer (PFE) reports strong second-quarter results. European Commission approves Pfizer and Bristol-Myers' (BMY) medicines.

                              TESARO (TSRO) Misses Earnings and Revenue Estimates in Q2

                              TESARO (TSRO) misses estimates for both earnings and revenues in the second quarter but beats on revenues. Zejula sales increase.

                                Drug Stocks to Report Q2 Earnings on Jul 31: PFE, INCY, ECYT

                                Let's see how pharma/biotech stocks are poised ahead of their scheduled results on Jul 31.

                                  Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV's Elagolix Gets FDA Nod

                                  Earnings are in focus this week with Lilly (LLY), Allergan (AGN) and Glaxo (GSK) delivering strong Q2 numbers. AbbVie (ABBV) gains FDA approval for Elagolix.

                                    Merck (MRK) Q2 Earnings & Sales Top on Keytruda Strength

                                    Merck (MRK) beat estimates for both earnings and sales in second-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.

                                      AstraZeneca's (AZN) Q2 Earnings and Sales Beat, Stock Up

                                      AstraZeneca (AZN) beats earnings and sales estimates in the second quarter on the back of strong new product sales and maintains previously issued outlook for 2018.

                                        AstraZeneca Sells Atacand's European Rights to Cheplapharm

                                        AstraZeneca (AZN) sells Atacand and Atacand Plus' European rights to Cheplapharm Arzneimittel for $210 million.

                                          Ironwood Begins New Phase III Study to Expand Linzess Label

                                          Ironwood (IRWD) commences a phase IIIb study in order to add a couple of new symptoms like bloating and discomfort associated with IBS-C to Linzess' label.

                                            Novartis Looks to Exit Antibacterial, Antiviral Program

                                            Per media sources, Novartis is looking to exit its antibacterial and antiviral research program, and cut its headcount.

                                              Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit

                                              Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.

                                                Biogen's Alzheimer Disease Candidate Succeeds in Phase II

                                                Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.

                                                  Clovis Gets EU Acceptance for Rubraca Label Expansion Filing

                                                  Clovis Oncology's (CLVS) regulatory application seeking label expansion of Rubraca as maintenance treatment was accepted for review in Europe.